Download presentation
Presentation is loading. Please wait.
Published byFrancis Robertson Modified over 5 years ago
1
The antifibrotic activity of pirfenidone in preclinical models of pulmonary fibrosis. a) Experimental design and effects of prophylactic pirfenidone treatment on bleomycin-induced pulmonary fibrosis [38]. b) Effects of delayed pirfenidone treatment on bleom... The antifibrotic activity of pirfenidone in preclinical models of pulmonary fibrosis. a) Experimental design and effects of prophylactic pirfenidone treatment on bleomycin-induced pulmonary fibrosis [38]. b) Effects of delayed pirfenidone treatment on bleomycin-induced pulmonary fibrosis (H. Oku, Shionogi and Co. Ltd, Osaka, Japan; personal communication). c) Effects of prophylactic pirfenidone treatment on bleomycin-induced pulmonary fibrosis [44]. d) Experimental design and effects of pirfenidone in an orthotopic lung transplant model [45]. e) The effects of pirfenidone in a mouse model of airway remodelling and hyperresponsiveness induced by sensitisation and challenge with ovalbumin [47]. BAL: bronchoalveolar lavage; bFGF: basic fibroblast growth factor; IL: interleukin; IFN: interferon; OVA: ovalbumin; PDGF: platelet-derived growth factor; SD: Sprague-Dawley; SDF: stromal cell-derived factor; TGF: transforming growth factor. C.J. Schaefer et al. Eur Respir Rev 2011;20:85-97 ©2011 by European Respiratory Society
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.